PBPK modeling and simulation in drug research and development

被引:0
|
作者
Xiaomei Zhuang [1 ]
Chuang Lu [2 ]
机构
[1] State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacology and Toxicology
[2] Department of DMPK,Biogen,Inc.
关键词
PBPK; PK prediction; Absorption; Metabolism; Drug–drug interaction; Special population;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Physiologically based pharmacokinetic(PBPK) modeling and simulation can be used to predict the pharmacokinetic behavior of drugs in humans using preclinical data.It can also explore the effects of various physiologic parameters such as age,ethnicity,or disease status on human pharmacokinetics,as well as guide dose and dose regiment selection and aid drug–drug interaction risk assessment.PBPK modeling has developed rapidly in the last decade within both the field of academia and the pharmaceutical industry,and has become an integral tool in drug discovery and development.In this mini-review,the concept and methodology of PBPK modeling are briefly introduced.Several case studies were discussed on how PBPK modeling and simulation can be utilized through various stages of drug discovery and development.These case studies are from our own work and the literature for better understanding of the absorption,distribution,metabolism and excretion(ADME) of a drug candidate,and the applications to increase efficiency,reduce the need for animal studies,and perhaps to replace clinical trials.The regulatory acceptance and industrial practices around PBPK modeling and simulation is also discussed.
引用
收藏
页码:430 / 440
页数:11
相关论文
共 50 条
  • [21] QUALIFICATION AND APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATION (MANDS) TO PREDICT DRUG-DRUG INTERACTIONS FOR ALISERTIB
    Patel, C.
    Ananthula, H.
    Zhou, X.
    Xia, C.
    Chowdhury, S.
    Zhu, A.
    Pusalkar, S.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S82 - S82
  • [22] Prediction of Drug-Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
    Ji, Beihong
    Liu, Shuhan
    Xue, Ying
    He, Xibing
    Viet Hoang Man
    Xie, Xiang-Qun
    Wang, Junmei
    DRUGS IN R&D, 2019, 19 (03) : 297 - 305
  • [23] Pharmacokinetic/pharmacodynamic modeling in drug research and development
    Derendorf, H
    Lesko, LJ
    Chaikin, P
    Colburn, WA
    Lee, P
    Miller, R
    Powell, R
    Rhodes, G
    Stanski, D
    Venitz, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (12): : 1399 - 1418
  • [24] APPLICATION OF PBPK MODELING TO EVALUATE PHARMACOKINETIC DRUG-DRUG INTERACTIONS DURING THE DEVELOPMENT OF NEW ANTIMALARIAL COMBINATION THERAPIES
    Abla, Nada
    Almond, Lisa
    Dickins, Maurice
    Gobeau, Nathalie
    Charman, Susan A.
    Rowland-Yeo, Karen
    El Gaaloul, Myriam
    Barter, Zoe
    Moehrle, Joerg
    Wesche, David
    Burrows, Jeremy
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S68 - S69
  • [25] Application of PBPK modelling in drug discovery and development at Pfizer
    Jones, Hannah M.
    Dickins, Maurice
    Youdim, Kuresh
    Gosset, James R.
    Attkins, Neil J.
    Hay, Tanya L.
    Gurrell, Ian K.
    Logan, Y. Raj
    Bungay, Peter J.
    Jones, Barry C.
    Gardner, Iain B.
    XENOBIOTICA, 2012, 42 (01) : 94 - 106
  • [26] Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
    Teerachat Saeheng
    Kesara Na-Bangchang
    Juntra Karbwang
    European Journal of Clinical Pharmacology, 2018, 74 : 1365 - 1376
  • [27] PBPK MODELING AND SIMULATION IN CHILDREN FOR TAPENTADOL METABOLIZED THROUGH GLUCURONIDATION
    Ravenstijn, P. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S37 - S37
  • [28] Modeling and simulation in drug development: Application to a drug for an unmet need.
    Sekar, VJ
    Gobburu, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P90 - P90
  • [29] Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation
    Franchetti, Yoko
    Nolin, Thomas D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 : S36 - S51
  • [30] Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
    Heiskanen, Tomi
    Heiskanen, Tomas
    Kairemo, Kalevi
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (09) : 988 - 1007